John Stellwagen

Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors

Tara Rheault, John Stellwagen, George M. Adjabeng et al. · ACS Medicinal Chemistry Letters · 2013 · 253 citations · Full text

B-raf-driven Tumors, Antitumor Activity, Hyperactive Signaling +16

Sulfonamides as Selective Na_V1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity

Russell F. Graceffa, Alessandro A. Boezio, Jessica Able et al. · Journal of Medicinal Chemistry · 2017 · 66 citations · Full text

Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation

Sylvie Laquerre, Marc R. Arnone, Katherine G. Moss et al. · Molecular Cancer Therapeutics · 2009 · 54 citations

Tumor Regression, B-rafv600e Mutation, Cell Death +19

The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer

Richard T. Lewis, Christiane Bode, Deborah M. Choquette et al. · Journal of Medicinal Chemistry · 2012 · 43 citations · Full text

Pharmaceutical Chemistry, Anaplastic Lymphoma Kinase, Tumor Biology +16

Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors

Emily A. Peterson, Alessandro A. Boezio, Paul S. Andrews et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 36 citations · Full text

Medicinal Chemistry, Drug Target, Biochemistry +13